Multiple myeloma is a blood cancer in which malignant plasma cells accumulate in the bone marrow, crowding out normal blood cell production and damaging bone. Research has advanced rapidly in understanding its biology, improving diagnostics, and expanding treatment options.

At the molecular level, multiple myeloma is driven by genetic abnormalities such as chromosomal translocations involving immunoglobulin genes, copy number changes, and mutations that alter cell growth and survival. These changes interact with signals from the bone marrow microenvironment, including stromal cells and cytokines like interleukin 6, which support myeloma cell survival and drug resistance. This interaction helps explain disease persistence and relapse.

Clinically, the disease often progresses from asymptomatic precursor stages, monoclonal gammopathy of undetermined significance and smoldering myeloma. Risk stratification now relies on combinations of serum biomarkers, bone marrow findings, imaging, and cytogenetic profiles to identify who is likely to progress and who may benefit from early intervention.

Treatment research has transformed outcomes. Proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies targeting surface proteins such as CD38 and SLAMF7 have significantly prolonged survival. Novel cellular and immune therapies, including chimeric antigen receptor T cells and bispecific antibodies targeting B cell maturation antigen and other antigens, are achieving deep, sometimes minimal residual disease negative responses in relapsed and refractory patients.

Current research focuses on overcoming resistance, optimizing treatment sequences, tailoring intensity to patient risk and frailty, and developing combinations that deliver durable control with fewer side effects. Long term management remains challenging, but the disease is increasingly treated as a chronic, controllable condition for many patients.